Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI Worldwide, MilanCPhI Worldwide, Milan
Not Confirmed
Not Confirmed
08-10 October, 2024
Discovery on TargetDiscovery on Target
Not Confirmed
Not Confirmed
30 September-03 October, 2024
Not Confirmed
Not Confirmed
30 September-02 October, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI Worldwide, MilanCPhI Worldwide, Milan
Industry Trade Show
Not Confirmed
08-10 October, 2024
Discovery on TargetDiscovery on Target
Industry Trade Show
Not Confirmed
30 September-03 October, 2024
Industry Trade Show
Not Confirmed
30 September-02 October, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/ice-is-pioneering-sustainability-innovation-in-bile-acid-research-for-neurodegenerative-diseases
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/2024-us-elections-harris-trump-differ-on-abortion-rights-aca-public-health-spends-agree-on-need-to-cut-drug-prices
20 Feb 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/iterion-therapeutics-announces-first-patient-dosed-in-phase-1b2a-clinical-trial-of-tegavivint-in-patients-with-advanced-hepatocellular-carcinoma-who-have-failed-one-or-more-systemic-treatments-302065477.html
16 May 2023
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/iterion-therapeutics-announces-the-initiation-of-a-phase-1-clinical-trial-for-tegavivint-in-patients-with-c-myc-overexpressing-relapsed-or-refractory-large-b-cell-lymphomas-301825538.html
01 Jun 2022
// PRNEWSWIRE
https://www.prnewswire.com/news-releases/iterion-therapeutics-announces-results-from-phase-1-dose-escalation-study-of-tegavivint-in-desmoid-tumors-to-be-presented-at-the-2022-asco-annual-meeting-301558729.html
08 Apr 2022
// PRNEWSWIRE
https://www.prnewswire.com/news-releases/iterion-therapeutics-announces-presentation-of-three-posters-involving-research-into-tegavivint-at-the-aacr-2022-annual-meeting-301520693.html
10 Nov 2021
// CLINICALTRIALSARENA
https://www.clinicaltrialsarena.com/news/iterion-phase-i-ii-trial-tegavivint-paediatric-cancers/
09 Nov 2021
// CLINICALTRIALSARENA
https://www.clinicaltrialsarena.com/news/iterion-phase-i-ii-trial-tegavivint-paediatric-cancers/
Details:
BC2059 (tegavivint) is a small molecule inhibitors of Transducin beta-like protein 1 (TBL1), which is being evaluated for the treatment of advanced hepatocellular carcinoma.
Lead Product(s): Tegavivint,Pembrolizumab
Therapeutic Area: Oncology Brand Name: BC2059
Study Phase: Phase I/ Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 20, 2024
Lead Product(s) : Tegavivint,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : BC2059 (tegavivint) is a small molecule inhibitors of Transducin beta-like protein 1 (TBL1), which is being evaluated for the treatment of advanced hepatocellular carcinoma.
Brand Name : BC2059
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 20, 2024
Details:
BC2059 (tegavivint) is a first-in-class small molecule inhibitor of Transducin beta-like protein 1 (TBL1), it is being investigated in patients with c-Myc-overexpressing relapsed or refractory large B-Cell lymphomas.
Lead Product(s): Tegavivint
Therapeutic Area: Oncology Brand Name: BC2059
Study Phase: Phase IProduct Type: Small molecule
Sponsor: National Cancer Institute
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 16, 2023
Lead Product(s) : Tegavivint
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : National Cancer Institute
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : BC2059 (tegavivint) is a first-in-class small molecule inhibitor of Transducin beta-like protein 1 (TBL1), it is being investigated in patients with c-Myc-overexpressing relapsed or refractory large B-Cell lymphomas.
Brand Name : BC2059
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 16, 2023
Details:
Data demonstrated that BC2059 (tegavivint), a first-in-class TBL1 inhibitor is well tolerated, does not appear to have the toxicity historically associated with WNT inhibition, and has promising clinical activity.
Lead Product(s): Tegavivint
Therapeutic Area: Oncology Brand Name: BC2059
Study Phase: Phase I/ Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2022
Lead Product(s) : Tegavivint
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Data demonstrated that BC2059 (tegavivint), a first-in-class TBL1 inhibitor is well tolerated, does not appear to have the toxicity historically associated with WNT inhibition, and has promising clinical activity.
Brand Name : BC2059
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 01, 2022
Details:
Tegavivint, a potent and selective small molecule that binds to TBL1 was well tolerated with grade 3 treatment-related adverse events reported in four patients for hypophosphatemia, stomatitis, headache, and elevated ALT; no grade 4 or 5 TRAEs were observed.
Lead Product(s): Tegavivint
Therapeutic Area: Oncology Brand Name: BC2059
Study Phase: Phase IProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2022
Lead Product(s) : Tegavivint
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Tegavivint, a potent and selective small molecule that binds to TBL1 was well tolerated with grade 3 treatment-related adverse events reported in four patients for hypophosphatemia, stomatitis, headache, and elevated ALT; no grade 4 or 5 TRAEs were obser...
Brand Name : BC2059
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 08, 2022
Details:
Tegavivint is a potent and selective first-in-class small molecule inhibitor of Transducin Beta-like Protein One (TBL1), a novel downstream target in the Wnt/beta-catenin signaling pathway.
Lead Product(s): Tegavivint
Therapeutic Area: Oncology Brand Name: BC2059
Study Phase: Phase I/ Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2021
Lead Product(s) : Tegavivint
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Tegavivint is a potent and selective first-in-class small molecule inhibitor of Transducin Beta-like Protein One (TBL1), a novel downstream target in the Wnt/beta-catenin signaling pathway.
Brand Name : BC2059
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 09, 2021
Details:
Tegavivint is a potent and selective first-in-class inhibitor of Transducin βeta-like Protein One (TBL1), a novel downstream target in the Wnt/beta-catenin signaling pathway.
Lead Product(s): Tegavivint
Therapeutic Area: Oncology Brand Name: BC2059
Study Phase: Phase IProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2021
Lead Product(s) : Tegavivint
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Tegavivint is a potent and selective first-in-class inhibitor of Transducin βeta-like Protein One (TBL1), a novel downstream target in the Wnt/beta-catenin signaling pathway.
Brand Name : BC2059
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 19, 2021
Details:
Data from patients treated in the dose expansion portion of the trial reaffirmed Tegavivint's safety at the RP2D level. No dose-limiting toxicities or significant adverse events were observed.
Lead Product(s): Tegavivint
Therapeutic Area: Oncology Brand Name: BC2059
Study Phase: Phase I/ Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 13, 2021
Lead Product(s) : Tegavivint
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Data from patients treated in the dose expansion portion of the trial reaffirmed Tegavivint's safety at the RP2D level. No dose-limiting toxicities or significant adverse events were observed.
Brand Name : BC2059
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 13, 2021
Details:
Series B financing to support ongoing Phase 1/2a clinical trial of Tegavivint in desmoid tumors and initiation of clinical trials in acute myeloid leukemia, non-small cell lung cancer and pediatric cancers.
Lead Product(s): Tegavivint
Therapeutic Area: Oncology Brand Name: BC2059
Study Phase: Phase I/ Phase IIProduct Type: Small molecule
Sponsor: Lumira Ventures
Deal Size: $17.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing February 16, 2021
Lead Product(s) : Tegavivint
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Lumira Ventures
Deal Size : $17.0 million
Deal Type : Series B Financing
Details : Series B financing to support ongoing Phase 1/2a clinical trial of Tegavivint in desmoid tumors and initiation of clinical trials in acute myeloid leukemia, non-small cell lung cancer and pediatric cancers.
Brand Name : BC2059
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 16, 2021
Details:
Agreement will expand clinical development for a potent and selective small molecule,Tegavivint, targeting TBL1, a downstream target in the Wnt/b-catenin signaling pathway.
Lead Product(s): Tegavivint
Therapeutic Area: Oncology Brand Name: BC2059
Study Phase: Phase I/ Phase IIProduct Type: Small molecule
Sponsor: Apollomics Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 10, 2021
Lead Product(s) : Tegavivint
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Apollomics Inc
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Agreement will expand clinical development for a potent and selective small molecule,Tegavivint, targeting TBL1, a downstream target in the Wnt/b-catenin signaling pathway.
Brand Name : BC2059
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 10, 2021
Details:
Desmoid Tumor Program to Provide Springboard for Iterion to Initiate Additional Clinical Trials of Tegavivint in AML, Non-Small Cell Lung Cancer and Certain Pediatric Cancers.
Lead Product(s): Tegavivint
Therapeutic Area: Oncology Brand Name: BC2059
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 28, 2020
Lead Product(s) : Tegavivint
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Desmoid Tumor Program to Provide Springboard for Iterion to Initiate Additional Clinical Trials of Tegavivint in AML, Non-Small Cell Lung Cancer and Certain Pediatric Cancers.
Brand Name : BC2059
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 28, 2020
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?